Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cochlear implants cases in Missouri: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 23% on average (17 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 173 | 40% |
| 2020 | 5 | 118 | 43% |
| 2021 | 3 | 143 | 48% |
| 2022 | 4 | 179 | 51% |
| 2023 | 9 | 226 | 55% |
| 2024 | 4 | 129 | 57% |
| 2025 from claims | – | 126 102–148 | 58% |
| 2026 forecast | – | 127 99–159 | 58% |
| 2027 forecast | – | 127 94–168 | 59% |
| 2028 forecast | – | 128 90–176 | 60% |
| 2029 forecast | – | 128 87–184 | 60% |
| 2030 forecast | – | 128 84–191 | 61% |
Cochlear implantation, children and adults. Professional codes (what the surgeon bills): CPT 69930.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Missouri; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 4 | 209+11%/yr | +11%/yr | 0.2 | 0% | 320 in 2030+7.6%/yr |
| Illinois | 4 | 174+4.9%/yr | +4.9%/yr | 0.1 | 0% | 140 in 2030−3.2%/yr |
| Kansas | 5 | 140+40%/yr | +40%/yr | 0.3 | 0% | 220 in 2030+7.8%/yr |
| Minnesota | 4 | 131+1.6%/yr | +1.6%/yr | 0.3 | 0% | 180 in 2030+5.5%/yr |
| Michigan | 3 | 130−0.5%/yr | −0.5%/yr | 0.2 | 0% | 210 in 2030+8.1%/yr |
| Indiana | 3 | 115+1.3%/yr | +1.3%/yr | 0.2 | 38% | 100 in 2030−1.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 24 | 2,268−7.2%/yr | −7.2%/yr | 3.71.0× | 88% | 2,500 in 2030+1.7%/yr |
| Sleep apnea & airway implants | 11 | 224+173%/yr | +173%/yr | 0.31.8× | 0% | 150 in 2030−6.1%/yr |
| Ear tubes & middle ear surgery | 1 | 134−17%/yr | −17%/yr | 0.20.6× | 0% | 240 in 2030+10%/yr |
Cochlear implants in every state, and its device makers · Every procedure market in Missouri · Every state · Compare with Ohio
Cochlear leads with 93% of company spending on these surgeons in 2025, +7 pts on 2024.
In 2025, 8 companies reported engagement with Missouri’s surgeons worth $107K in consulting, speaking, meals and travel tied to these products, about $27K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 15 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.